anti-CD44vRA monoclonal antibody (MaimoniDex/Abmaxis/Merck & Co)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD44vRA monoclonal antibody (MaimoniDex/Abmaxis/Merck & Co)
Drug Alias NameCD44 monoclonal antibody (Abmaxis/MaimoniDex/Merck & Co)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsInflammationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMaimoniDex RA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbmaxis IncMaimoniDex RAMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsInflammationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A